109 related articles for article (PubMed ID: 8890971)
1. A new regimen of cisplatin, epirubicin and methotrexate (PEM-3) as primary chemotherapy for locally advanced bladder cancer.
Cacciari N; Martoni A; Rossi AP; Turci P; Lelli G; Martinelli A; Maver P; Corrado F; Mannini D; Reggiani A; Concetti S; Martelli A; Melotti B; Cricca A; Zamagni C; Pannuti F
Tumori; 1996; 82(4):364-8. PubMed ID: 8890971
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant CMV chemotherapy plus radical cystectomy in locally advanced bladder cancer: the impact of pathologic response on long-term results.
Scattoni V; Bolognesi A; Cozzarini C; Francesca F; Grasso M; Galli L; Torelli T; Campo B; Villa E; Rigatti P
Tumori; 1996; 82(5):463-9. PubMed ID: 9063525
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy with cisplatin, epirubicin, methotrexate in the treatment of locally advanced or metastatic transitional cell cancer of the bladder (TCC).
Lelli G; Melotti B; Pannuti F; Rossi AP; Maver P; Mannini D; Corrado G; Severini G; Bercovich E; Beghelli R
J Chemother; 1992 Aug; 4(4):239-43. PubMed ID: 1403081
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of a new combined primary chemotherapy regimen, intravenous methotrexate and vincristine and intraarterial adriamycin and cisplatin, for locally advanced urinary bladder cancer: preliminary results.
Kuroiwa T; Naito S; Hasuo K; Kishikawa T; Masuda K; Kumazawa J
Cancer Chemother Pharmacol; 1995; 35(5):357-63. PubMed ID: 7850915
[TBL] [Abstract][Full Text] [Related]
5. M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder.
Bellmunt J; Ribas A; Albanell J; Bermejo B; Vera R; De Torres JA; Morote J; Lopez-Pacios MA; Banus JM; Rovirosa A; Carulla J; Sole LA
Am J Clin Oncol; 1996 Aug; 19(4):344-8. PubMed ID: 8677901
[TBL] [Abstract][Full Text] [Related]
6. [Neoadjuvant chemotherapy with MVC (methotrexate, vinblastine, cisplatin)in the treatment of infiltrating transitional carcinoma of the bladder].
Campo B; Torelli T; Leidi GL; Corrada P; Bacchioni AM; Ordesi G; Zanitzer L
Arch Ital Urol Nefrol Androl; 1990 Jun; 62(2):237-42. PubMed ID: 2142807
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma.
Balbay MD; Ozen H; Uluçay S; Sahin A; Ergen A; Koçal C; Remzi D
Int Urol Nephrol; 1993; 25(4):351-7. PubMed ID: 8276565
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
[TBL] [Abstract][Full Text] [Related]
9. [Polychemotherapy using the M-VEC protocol (methotrexate, vinblastine, epirubicin, cisplatin) in advanced urinary bladder cancer--effectiveness and toxicity].
Rassweiler J; Rüther U; Bäuerle K; Bub P; Jipp P; Eisenberger F
Urologe A; 1989 Jan; 28(1):25-30. PubMed ID: 2922897
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with sequential methotrexate and 5-fluorouracil scheduling, epirubicin and cisplatin for locally advanced bladder cancer.
Nishiyama T; Tanikawa T; Tomita Y; Takahasi K
Oncology; 2002; 63(1):1-5. PubMed ID: 12187064
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
Choueiri TK; Jacobus S; Bellmunt J; Qu A; Appleman LJ; Tretter C; Bubley GJ; Stack EC; Signoretti S; Walsh M; Steele G; Hirsch M; Sweeney CJ; Taplin ME; Kibel AS; Krajewski KM; Kantoff PW; Ross RW; Rosenberg JE
J Clin Oncol; 2014 Jun; 32(18):1889-94. PubMed ID: 24821883
[TBL] [Abstract][Full Text] [Related]
13. DNA ploidy and S-phase fraction as predictive factors of response and outcome following neoadjuvant methotrexate, vinblastine, epirubicin and cisplatin (M-VEC) chemotherapy for invasive bladder cancer.
Türkölmez K; Baltaci S; Bedük Y; Müftüoğlu YZ; Göğüş O
Scand J Urol Nephrol; 2002 Feb; 36(1):46-51. PubMed ID: 12002357
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
15. Conservative treatment for T2-T4 bladder cancer with primary chemotherapy and radiotherapy: a pilot study.
Cruciani G; Dazzi C; Montanari F; Voce S; Salerno V; Giannini M; Emiliani E; Marangolo M
Tumori; 1993 Feb; 79(1):53-7. PubMed ID: 8497923
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
Kuroda M; Meguro N; Maeda O; Saiki S; Kinouchi T; Usami M; Kotake T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S9-13. PubMed ID: 7527736
[TBL] [Abstract][Full Text] [Related]
17. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
Hagan MP; Winter KA; Kaufman DS; Wajsman Z; Zietman AL; Heney NM; Toonkel LM; Jones CU; Roberts JD; Shipley WU
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):665-72. PubMed ID: 14529770
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
19. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study.
Fellin G; Graffer U; Bolner A; Ambrosini G; Caffo O; Luciani L
Br J Urol; 1997 Jul; 80(1):44-9. PubMed ID: 9240179
[TBL] [Abstract][Full Text] [Related]
20. Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: long-term followup of a prospective study.
de la Rosa F; Garcia-Carbonero R; Passas J; Rosino A; Lianes P; Paz-Ares L
J Urol; 2002 Jun; 167(6):2413-8. PubMed ID: 11992048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
